0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > B7-2

B7-2

Brief Information

Name:Cluster of differentiation 86
Target Synonym:FUN-1,CTLA-4 counter-receptor B7.2,CD28LG2,Activation B7-2 antigen,CD86,CD86 Molecule,CD86 Antigen (CD28 Antigen Ligand 2, B7-2 Antigen),BU63,B70,B-Lymphocyte Activation Antigen B7-2,T-Lymphocyte Activation Antigen CD86,B-Lymphocyte Antigen B7-2,CD86 Anti
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

CD6-H82F5-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) can bind to CD28 expressed on Jurkat E6.1 cells. The concentration of B7-2 used is 1.5 μg/mL (Routinely tested).

CD6-H82F5-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that the binding of Biotinylated Human B7-2, Fc,Avitag to CD28 expressed on Jurkat E6.1 was inhibited by increasing concentration of neutralizing Anti-CD28 antibody. The concentration of B7-2 used is 1.5 μg/mL. The IC50 is 0.031 μg/mL (Routinely tested).

CD6-C5254-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Cynomolgus / Rhesus macaque B7-2, Fc Tag (Cat. No. CD6-C5254) on Protein A Biosensor, can bind Human / Cynomolgus / Rhesus macaque CD28, His Tag (Cat. No. CD8-H52Hc) with an affinity constant of 11 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

CD6-H5223-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (Cat. No. CD8-H525a) on Protein A Biosensor, can bind Human B7-2, His Tag (Cat. No. CD6-H5223) with an affinity constant of 6.8 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Customer Reviews

Synonym Name

CD86,B7-2,B70,CD28LG2,LAB72,MGC34413

Background

Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon ¦Ã. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-¦ÊB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Belatacept LEA29Y; LEA-029; BMS-224818; L104EA29YIg Approved Bristol-Myers Squibb Company Nulojix EU Rejection of renal transplantation Bristol-Myers Squibb Pharma Eeig 2011-06-15 Rejection of renal transplantation; Rejection of organ transplantation Details
Abatacept BMS-188667; BMS-188667SC; ONO-4164SC; ONO-4164 Approved Bristol-Myers Squibb Company Orencia Mainland China Arthritis, Rheumatoid Bristol-Myers Squibb Company 2005-12-23 Nephrosis, Lipoid; Crohn Disease; Nephrotic Syndrome; Muscular Diseases; Colitis, Ulcerative; Arthritis, Psoriatic; Glomerulosclerosis, Focal Segmental; Psoriasis; Lupus Erythematosus, Systemic; Polymyositis; Multiple Sclerosis; Lupus Nephritis; Arthritis, Juvenile; Sjogren's Syndrome; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Dermatomyositis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs Phase 1 Clinical Hunan Zhaotai Yongren Biotech Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop